Your browser doesn't support javascript.
loading
NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge.
Guebre-Xabier, Mimi; Patel, Nita; Tian, Jing-Hui; Zhou, Bin; Maciejewski, Sonia; Lam, Kristal; Portnoff, Alyse D; Massare, Michael J; Frieman, Matthew B; Piedra, Pedro A; Ellingsworth, Larry; Glenn, Gregory; Smith, Gale.
Afiliação
  • Guebre-Xabier M; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: mguebre-xabier@Novavax.com.
  • Patel N; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: npatel@novavax.com.
  • Tian JH; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: jhtian@Novavax.com.
  • Zhou B; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: bzhou@Novavax.com.
  • Maciejewski S; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: smaciejewski@Novavavax.com.
  • Lam K; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: klam@Novavax.com.
  • Portnoff AD; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: aportnoff@Novavax.com.
  • Massare MJ; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: mmassare@Novavax.com.
  • Frieman MB; University of Maryland, School of Medicine, 685 West Baltimore St, Baltimore, MD 21201, USA. Electronic address: mfrieman@som.umaryland.edu.
  • Piedra PA; Department of Molecular Virology and Microbiology, and Pediatrics, Baylor College of Medicine, Houston, TX, USA. Electronic address: ppiedra@bcm.edu.
  • Ellingsworth L; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: lellingsworth@novavax.com.
  • Glenn G; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: gglenn@Novavax.com.
  • Smith G; Novavax, Inc., 21 Firstfield Road, Gaithersburg, MD 20878, USA. Electronic address: gsmith@Novavax.com.
Vaccine ; 38(50): 7892-7896, 2020 11 25.
Article em En | MEDLINE | ID: mdl-33139139
ABSTRACT
There is an urgent need for a safe and protective vaccine to control the global spread of SARS-CoV-2 and prevent COVID-19. Here, we report the immunogenicity and protective efficacy of a SARS-CoV-2 subunit vaccine (NVX-CoV2373) produced from the full-length SARS-CoV-2 spike (S) glycoprotein stabilized in the prefusion conformation. Cynomolgus macaques (Macaca fascicularis) immunized with NVX-CoV2373 and the saponin-based Matrix-M™ adjuvant induced anti-S antibody that was neutralizing and blocked binding to the human angiotensin-converting enzyme 2 (hACE2) receptor. Following intranasal and intratracheal challenge with SARS-CoV-2, immunized macaques were protected against upper and lower infection and pulmonary disease. These results support ongoing phase 1/2 clinical studies of the safety and immunogenicity of NVX-CoV2327 vaccine (NCT04368988).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 Limite: Adolescent / Adult / Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Vaccine Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 Limite: Adolescent / Adult / Aged / Animals / Female / Humans / Male / Middle aged Idioma: En Revista: Vaccine Ano de publicação: 2020 Tipo de documento: Article